Haim Belinson
CEO CaVos Biotherapeutics
Dr. Haim Belinson received a PhD. in neurobiology from the Tel Aviv University in Israel. Following postdoctoral training at the Department of Pediatrics, Institute for Human Genetics, UCSF, San Francisco, CA. where he studied brain development and the brain gut axis in the context of autism spectrum disorder, he joined Teva Pharmaceutical where he utilized broad neuroscience scientific expertise and lead pharmacology preclinical development of drugs for neurodegenerative diseases, neuropsychiatry and pain. At Teva, he dealt with both the scientific aspects as well as leading various stages of drug development from ideation to PhIII. Since 2018, Dr. Belinson led Bsense Bio Therapeutics as its CSO and later CEO in the development program of small molecule targeting sensory hyperexcitability from ideation to clinical candidate nomination. In 2025, Dr. Belinson joined caVos Biotherapeutics as its CEO, to lead the innovative approach of developing novel therapeutics based on naturally occurring resistance mechanisms.
Dr. Belinson has over 20 years of experience in R&D, spanning pharmaceutical R&D, target identification/validation, behavioral pharmacology and PK/PD.
Seminars
- Evolutionary AI Platform: Discovery of first-in-class therapeutic mRNA leads converged in long-lived species
- In Vitro Success: Hit-to-multicistronic mRNA translation, showcasing crosstalk in fibrosis modulation
- Next Steps: Advancing mRNA and LNP therapeutics toward IND
